AngioDynamics, Inc. provides earnings guidance for the fiscal year 2025. For the year, the company expects Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% ? 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.435 USD | +25.38% | +33.86% | -4.05% |
07:58pm | Sector Update: Health Care Stocks Gain in Afternoon Trading | MT |
06:01pm | AngioDynamics Shares Rise After Fiscal Q4 Results, Share Repurchase Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.27% | 238M | |
-6.76% | 179B | |
-5.71% | 98.84B | |
-5.41% | 65.34B | |
+15.46% | 45.41B | |
-6.91% | 44.94B | |
+9.70% | 43.76B | |
+13.43% | 29.01B | |
+19.39% | 25.65B | |
-6.66% | 23.32B |
- Stock Market
- Equities
- ANGO Stock
- News AngioDynamics, Inc.
- AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2025